Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MCF 10A Ceritinib
0.01
ALK
RTK
 0.9998 -0.00044
MCF 10A Ceritinib
0.031623
ALK
RTK
 0.9816 -0.00053
MCF 10A Ceritinib
0.1
ALK
RTK
 0.9635 -0.00161
MCF 10A Ceritinib
0.31623
ALK
RTK
 0.9190 -0.00259
MCF 10A Ceritinib
1.0
ALK
RTK
 0.7747 -0.00464
MCF 10A Ceritinib
3.1623
ALK
RTK
 0.5414 0.01676
MCF 10A Ceritinib
10.0
ALK
RTK
 -0.3186 0.46177
MCF 10A Neratinib
0.00031623
EGFR/HER2
RTK
 1.0022 -0.00084
MCF 10A Neratinib
0.001
EGFR/HER2
RTK
 1.0053 -0.00135
MCF 10A Neratinib
0.0031623
EGFR/HER2
RTK
 1.0018 -0.00088
MCF 10A Neratinib
0.01
EGFR/HER2
RTK
 0.9820 -0.00194
MCF 10A Neratinib
0.031623
EGFR/HER2
RTK
 0.7332 -0.00632
MCF 10A Neratinib
0.1
EGFR/HER2
RTK
 0.4937 -0.00434
MCF 10A Neratinib
0.31623
EGFR/HER2
RTK
 0.3007 0.00303
MCF 10A Neratinib
1.0
EGFR/HER2
RTK
 0.1802 0.04585
MCF 10A Neratinib
3.1623
EGFR/HER2
RTK
 0.0959 0.16019
MCF 10A Tivantinib
0.001
MET
RTK
 0.9985 0.00059
MCF 10A Tivantinib
0.0031623
MET
RTK
 1.0074 0.00074
MCF 10A Tivantinib
0.01
MET
RTK
 1.0082 0.00015
MCF 10A Tivantinib
0.031623
MET
RTK
 1.0037 0.00197
MCF 10A Tivantinib
0.1
MET
RTK
 0.8214 0.01076
MCF 10A Tivantinib
0.31623
MET
RTK
 0.1582 0.25655
MCF 10A Tivantinib
1.0
MET
RTK
 0.0482 0.32404
MCF 10A Tivantinib
3.1623
MET
RTK
 -0.0788 0.33510
MCF 10A Tivantinib
10.0
MET
RTK
 -0.1502 0.41791